Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bolesta, S.
Right arrow Articles by Roslund, B. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bolesta, S.
Right arrow Articles by Roslund, B. P.
American Journal of Health-System Pharmacy, Vol. 65, Issue 1, 37-41
Copyright © 2008. American Society of Health-System Pharmacists, Inc. All rights reserved. 1079-2082/04/0602-1242$06.00


Case Report

Elevated hepatic transaminases associated with telithromycin therapy: A case report and literature review

Scott Bolesta and Brian P. Roslund

SCOTT BOLESTA, PHARMD.,. is Assistant Professor, Department of Pharmacy Practice, Nesbitt College of Pharmacy and Nursing, Wilkes University, Wilkes-Barre, PA, and Clinical Pharmacist, Department of Pharmacy, Mercy Hospital, Scranton, PA. BRIAN P. ROSLUND, PHARMD., is Pharmacy Practice Resident, Department of Pharmacy,. Thomas Jefferson University Hospital, Philadelphia, PA.

Address correspondence to Dr. Bolesta at the Department of Pharmacy Practice, Nesbitt College of Pharmacy and Nursing, Wilkes University, 84 West South Street, Wilkes-Barre, PA 18766 (scott.bolesta{at}wilkes.edu).


Purpose. A case of mild hepatocellular injury associated with the administration of telithromycin in a patient with no risk factors for hepatotoxicity is presented.

Summary. A 44-year-old man with no significant past medical history arrived at the emergency room after six days of high fever, chills, headache, neck stiffness, and back pain. Five days earlier, he visited a family medicine clinic for his symptoms and oral telithromycin 800 mg daily was prescribed for a suspected upper-respiratory-tract infection. The patient stopped taking the drug after three days due to persistent symptoms. On admission, the patient’s laboratory tests revealed an aspartate transaminase (AST) concentration of 68 units/L, an alanine transaminase (ALT) value of 155 units/L, and an erythrocyte sedimentation rate of 40 mm/hr. The patient was not taking any long-term medications, had taken only aspirin for his fever, and denied the use of alcohol and illegal drugs. The patient was admitted to the general medical unit with a diagnosis of possible viral hepatitis. His urine culture was negative, and serology tests later revealed no evidence of hepatitis A, B, or C. Ibuprofen, pantoprazole, and enoxaparin were prescribed. On hospital day 2, the patient’s AST and ALT concentrations had decreased to 50 and 110 units/L, respectively. By day 3, the patient’s symptoms had improved and he remained afebrile. His AST and ALT values had further decreased to 41 and 105 units/L, respectively. He was then diagnosed with acute viral upper-respiratory-tract infection with mild hepatotoxicity associated with telithromycin and was discharged home with orders for follow-up at the family medicine clinic.

Conclusion. A patient without risk factors for hepatotoxicity developed mild elevations in hepatic transaminases after receiving telithromycin for the treatment of a suspected upper-respiratory-tract infection.

Index terms: Anticoagulants; Antiinflammatory agents; Enoxaparin; Gastrointestinal drugs; Ibuprofen; Liver diseases; Macrolides; Pantoprazole; Respiratory tract infections; Telithromycin; Toxicity

 






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Society of Health-System Pharmacists.